| Name | Title | Contact Details |
|---|---|---|
Krupalini Balasubramanya |
CHRO | Profile |
Takeda San Francisco is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Mosaic`s biopharmaceutical teams turn ideas into reality. We provide experienced biopharma leadership and cross-functional teams to accelerate your protein therapeutic research and development program
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion`s lead program, FPI-1434, is currently in a Phase 1 clinical trial. Fusion is headquartered in Hamilton, ON, with offices in Boston, MA.
ARLG addresses antibacterial resistance through innovative clinical trial design, unique access to clinically well-characterized bacteria, and opportunities for early-stage investigators.